Quarterly report pursuant to Section 13 or 15(d)

Segment Reporting (Tables)

v3.22.1
Segment Reporting (Tables)
3 Months Ended
Mar. 31, 2022
Segment Reporting [Abstract]  
Schedule of Reconciliation of Revenue from Segments to Consolidated The following table provides a reconciliation of revenue and operating income by reportable segment to consolidated results and was derived from each segment’s internal financial information as used for corporate management purposes (in thousands):
Three Months Ended March 31,
2022 2021
OmniAb business revenue
  Royalties $ 263  $ — 
  Contract 8,915  8,559 
Total OmniAb business revenue
9,178  8,559 
Ligand core business revenue
  Royalties 13,432  7,112 
  Captisol - Core 6,226  1,253 
  Captisol - COVID 5,896  30,019 
  Contract 10,961  8,207 
 Total Ligand core business revenue 36,515  46,591 
     Total revenue $ 45,693  $ 55,150 
Segment operating income (loss)
OmniAb business
$ (6,189) $ (4,604)
Ligand core business 9,991  18,446 
Total segment operating income 3,802  13,842 
Unallocated corporate items
Shared-based compensation 5,657  4,870 
Other corporate expenses 7,451  4,257 
  Total unallocated corporate items 13,108  9,127 
Income (loss) from operations $ (9,306) $ 4,715